Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2024-04-10 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2024-04-10 English
Definitive agreement with certain institutional investors providing for the issuance and sale in a registered direct offering of 7,500,000 ADSs and warrants to purchase up to an aggregate of 7,500,00
Regulatory Filings Classification · 99% confidence The document explicitly identifies itself as a "FORM 6-K" which is a "REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934". Form 6-K filings are used to report material information that a foreign private issuer is required to disclose to its home country regulators or stock exchange, or that it makes public in its home country. This type of filing is generally used for current reports that do not fit neatly into the periodic reporting requirements of Form 20-F (the annual report equivalent). Since the provided definitions do not have a specific code for Form 6-K, and it is a mandatory regulatory filing reporting material events (in this case, a registered direct offering/financing), the most appropriate general category is 'Regulatory Filings' (RNS), as it serves as a catch-all for required SEC submissions that aren't 10-K, AR, or specific proxy/insider forms. The content details a capital raising event (issuance and sale of ADSs and Warrants), which relates to 'CAP' (Capital/Financing Update), but the document *form* itself is the regulatory filing reporting this event. Given the structure and explicit mention of SEC forms (Form 6-K, Form F-3), RNS is the best fit for the filing type itself, as it is a general regulatory disclosure.
2024-04-01 English
Definitive agreement with certain institutional investors providing for the issuance and sale in a registered direct offering of 7,500,000 ADSs and warrants to purchase up to an aggregate of 7,500,00
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Direct offering* *FORM_6-K_1-Apr-2024_isa.pdf*'. The document itself is very short (1767 characters) and serves primarily to announce the availability of an attached report (Form 6-K, which is typically used for foreign private issuers to report material events). According to Rule 2, when a document announces the publication of another report rather than containing the full content, it should be classified as a Report Publication Announcement (RPA). Since this is an announcement about a filing/report, RPA is the most appropriate classification.
2024-04-01 English
PROSPECTUS SUPPLEMENT - 7,500,000 ADS and Warrants to Purchase 7,500,000 ADS
Capital/Financing Update Classification · 98% confidence The document explicitly uses the title "PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024)" and details an offering of American Depositary Shares (ADSs) and Warrants, including pricing, placement agent fees, and expected delivery dates. This structure, including the table of contents referencing sections like 'Risk Factors,' 'Use of Proceeds,' and 'Plan of Distribution' within a prospectus framework, is characteristic of a securities offering document filed with the SEC. Since this document is a supplement to a base prospectus detailing the terms of a specific offering (the sale of securities), it falls under the category of Capital/Financing Update (CAP) as it directly relates to fundraising and capital structure changes through the issuance of new securities. It is not a standard periodic report (10-K, IR) or a simple announcement (RPA/RNS).
2024-04-01 English
PROSPECTUS SUPPLEMENT - 7,500,000 ADS and Warrants to Purchase 7,500,000 ADS
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The key content states: 'Attached hereto is a report on *Prospectus supplement* *FORM_424B5_Apr-2024_isa.pdf*'. A Form 424B5 is a prospectus supplement related to the offering of securities, which falls under financing or capital activities. However, the document itself is very short (1779 chars) and explicitly announces the attachment of the actual report ('Prospectus supplement'). According to Rule 2, this indicates a Report Publication Announcement (RPA) rather than the detailed financing document itself (which might be classified as CAP if it were the full prospectus). Since it is an announcement about the publication of a specific regulatory document (prospectus supplement), RPA is the most appropriate classification.
2024-04-01 English
6-K
Regulatory Filings
2024-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.